Navigation Links
Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
Date:8/19/2007

KING OF PRUSSIA, Pa., Aug. 2 /PRNewswire/ -- Cytokine PharmaSciences, Inc. (CPSI) today revealed that recent experiments with its small-molecule MIF inhibitors showed oral efficacy in animal models. Based on these results, the Company announced that it is advancing one of these compounds into preclinical development.

Macrophage Migration Inhibitory Factor, or MIF, is linked to many conditions, including arthritis, asthma, cancer, sepsis, inflammatory bowel disease and various infections and autoimmune disorders. Neutralization of MIF biological activity has been shown to have a protective effect against these diseases. CPSI has an extensive patent portfolio focused on MIF, covering various methods for neutralization, including small molecules. These compounds were recently shown to be effective in animal models of multiple sclerosis (MS) and arthritis when administered orally.

The MS animal experiments were conducted in the laboratories of Dr. Abhay Satoskar and Dr. Caroline C. Whitacre, both of Ohio State University in Columbus, OH. Dr. Satoskar stated: "The therapeutic efficacy of these compounds was impressive with no outward signs of toxicity. These findings indicate that small-molecule MIF inhibitors are viable drug candidates for treating other autoimmune and inflammatory diseases in which MIF has been identified as a pathogenic factor." Dr. Whitacre adds: "The inhibitors were especially effective in treating disease that had already started, which is traditionally the most difficult hurdle for a new therapy. We are very encouraged by these results."

The arthritis experiments were conducted under the guidance of Drs. Thais M. Sielecki and Vidal F. de la Cruz of Cytokine PharmaSciences, Inc. Dr. Sielecki observed: "We are encouraged to have a small molecule MIF inhibitor that is orally active. MIF is an important target in many diseases and an oral treatment is a definite advantage." Dr. Sielecki will present the MS and arthritis results at the annual American Chemical Society conference on August 22, 2007, in Boston, MA.

Cytokine PharmaSciences is a biopharmaceutical company located in King of Prussia (near Philadelphia), Pennsylvania. The company licenses technologies from academia and other sources, develops products from those technologies and outlicenses the products to third parties for marketing. For more information, visit to http://www.cytokinepharmasciences.com .


'/>"/>
SOURCE Cytokine PharmaSciences, Inc.

Copyright©2007 PR Newswire.

Related medicine technology :

1. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
2. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
3. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
4. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
5. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
6. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
7. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
8. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
9. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
10. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
11. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... The Rebound mobile app is poised to become ... tide of prescription drug addiction. The app empowers users to ... stepping down their dosage in a safe, controlled manner while ... the first 100,000 people to sign up will enjoy 3 ... ...
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... PurhealthRX , a leading Health and Nutrition Company, is announcing the ... spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the amount ... into liquid products, while reducing costs to end users. , The team of researchers ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of ... collection of specialty vendors and unique items from across the nation, this holiday-themed event ... wellness services offered by the VNA. The boutique will be open Saturday, November ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Planet Fitness, one ... U.S., announced today its plans to open a flagship location in Covington, LA at ... former Rooms To Go store next to Office Depot in the Holiday Square shopping ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
Breaking Medicine News(10 mins):